Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Jan. 11, 2024 /PRNewswire/ -- Johnson Fistel, LLP is investigating Grifols, S.A. (NASDAQ: GRFS), for potential securities law violations.

GRFS SHAREHOLDER ALERT: Johnson Fistel Investigates Grifols, S.A. Following Short Seller Report

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Grifols, S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 8, 2024, after the market closed, Gotham City Research published a report alleging, among other things, that Grifols manipulated its debt and EBITDA figures to artifici.

The Law Offices of Frank R. Cruz Announces Investigation of Grifols, S.A.

The CEO of Spanish pharma company Grifols said there was room to improve communications and governance of the company, but a negative report by Gotham City Research that questioned its accounting was "absolutely wrong".

Grifols CEO says Gotham report is wrong, pledges to improve governance

NEW YORK , Jan. 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially misleading business information to the investing public.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF

Gotham City's recent allegations against Grifols have caused GFRS stock to significantly decline. Our team at Mare will remain waiting for clarifications. We expect the company's stock to be under pressure in the short term and probably not investable. For this reason, we are now neutral. On positive news, Grifols reached an alliance with Haier Group and raised SRAAS' proceeds to $1.8 billion.

Grifols: Wait And See For Now

Shares of Grifols rallied 8% on Wednesday, after the short-seller who criticized the Spanish drug company's accounting practices sharply reduced its negative bet on the stock.

Blood-plasma group's shares rally after short seller slashes negative bet

Spain's pharmaceutical company Grifols will seek a compensation at least equivalent to the share price loss prompted by short seller Gotham City Research's Tuesday report in the lawsuit it plans to launch, a board member told Reuters on Wednesday.

Grifols to seek compensation from Gotham at least equivalent to share loss - board member

Grifols' position in the pharma industry has dropped due to a short-seller report, causing its stock to decline. The report questions the accounting treatment of M&As and consolidation of entities in Grifols' filings. I believe that the allegations in the report are not significant enough to warrant a 20% drop in the company's stock and plans to wait for a reaction before adding more to their stake.

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Spanish drugmaker Grifols, whose shares slumped on Tuesday after hedge fund Gotham City Research questioned its accounts, has grown from a family-run blood testing lab founded in Barcelona in 1909 to a global firm with a big U.S. presence.

What is Grifols and why have its shares slumped?

Shares of Spanish pharmaceutical company Grifols (NASDAQ: GRFS ) are plunging lower following the publication of a short report from Gotham City Research. The research firm has alleged that Grifols has been manipulating its financial metrics.

10 Things to Know as Gotham City Slams Grifols (GRFS) Stock in New Short Report

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Grifols securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting.

ROSEN, A LEADING NATIONAL FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF

The head of the Spanish CNMV stock market supervisor Rodrigo Buenaventura said it made no sense to question the integrity of the audited accounts of drugmaker Grifols or to ignore a report on Tuesday by Gotham City Research which did so.

Spanish market supervisor says it makes no sense to query Grifols accounts

Grifols (NASDAQ: GRFS ) stock is falling hard on Tuesday after the company was hit with criticism from hedge fund Gotham City Research. The report against Grifols highlights several issues that Gotham City Research has with the Spanish plasma therapeutic company.

Why Is Grifols (GRFS) Stock Down 38% Today?

Spanish blood plasma company Grifols saw its shares plunge more than 40% at one point on Tuesday after hedge fund Gotham City Research questioned the Madrid-listed group's financial reporting.

Spanish blood plasma company stock tumbles after short-seller research report

Spanish pharmaceutical company Grifols is set to hold a board meeting on Tuesday afternoon in reaction to a report from Gotham City Research questioning the company's accounting released earlier, board member Tomas Daga told Reuters.

Grifols to hold board meeting Tuesday afternoon after Gotham City report

Shares in Spanish drug company Grifols plunged more than 40% on Tuesday after hedge fund Gotham City Research alleged its debt ratios are roughly double those officially reported.

Shares of Spanish drugmaker Grifols plunge after hedge fund queries debt ratios

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Grifols (GRFS) is a Great Choice

The Phase 1 trial will be conducted by researchers from the National Cancer Institute as part of a Cooperative Research and Development Agreement (CRADA)

GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors

Denison Mines

Macatawa Bank

Navient

NGL Energy Partners

Grifols (GRFS), Denison Mine Corp (DNN), NGL Energy Partners (NGL), Macatawa Bank (MCBC) and Navient (NAVI) have been selected as the breakout stocks for today.

5 Best Breakout Stocks to Invest in for Attractive Returns

Argenx's failure removes competitive pressure on Grifols' immunoglobulin franchise. Grifols is in advanced negotiations to sell Shanghai RAAS, which would eliminate short-term debt concerns. Grifols' Q3 results showed increased sales, improved EBITDA margin, and higher plasma supply. Our buy rating is then confirmed.

Grifols Is Building Momentum

BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV).

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Researchers from the National Cancer Institute will conduct the Phase 1 trial , as established in a recently signed Cooperative Research and Development Agreement (CRADA)

GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

Grifols, S.A. (NASDAQ:GRFS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo - CFO Conference Call Participants Thomas Jones - Joh.

Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript

Grifols shares soared in early trading on Thursday after the Spanish drugmaker upgraded its annual profit outlook following a strong quarter.

Grifols shares soar after 2023 profit outlook upgrade

ZARAGOZA, Spain, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD). Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.

News for Grifols, S.A. Stock (GRFS)